Transactions in connection with share buy-back program
Company Announcement
COPENHAGEN, Denmark; March 13, 2023 –Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.
The share buy-back program is expected to be completed no later than March 31, 2023 and comprises up to 220,000 shares.
The following transactions were executed under the program from March 6, 2023, to March 10, 2023:
| No. of shares | Average price (DKK) | Total value (DKK) | |
| Accumulated through last announcement | 78,000 | 204,581,960 | |
| March 06, 2023 | 12,000 | 2,560.23 | 30,722,760 |
| March 07, 2023 | 10,000 | 2,541.68 | 25,416,800 |
| March 08,2023 | 10,000 | 2,497.98 | 24,979,800 |
| March 09, 2023 | 11,000 | 2,503.10 | 27,534,100 |
| March 10, 2023 | 12,000 | 2,468.01 | 29,616,120 |
| Total | 55,000 | 138,269,580 | |
| Accumulated under the program | 133,000 | 342,851,540 |
Details of each transaction are included as an appendix to this announcement.
Following these transactions, Genmab holds 676,416 shares as treasury shares, corresponding to 1.03% of the total share capital and voting rights.
The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 06 dated February 22, 2023.
About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Global Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.
Company Announcement no. 14
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachments
- 230313_CA14_Transactions in connections with share buyback program - Mar 10 2023
- Appendix_SBBP_specification for March 6 to March 10
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Medium-term Fiscal Strategy Plan 2024-2028: to counter inflation, safeguard living standards and support growth29.3.2023 20:11:00 CEST | Press release
The government's fiscal strategy plan for the next five years lays out its strategy to utilise fiscal policy in a targeted manner to counter inflation and overheating by increasing expenditure restraint and revenue generation and postponing public investments. At the same time, important basic services that the government has significantly reinforced in recent years are maintained, based on the strong position of the Treasury. Financial support will be provided for those groups least able to withstand the impact of rising inflation, as was done with the government's support actions during the pandemic and the previous year. The Treasury’s fiscal position has improved significantly in recent quarters , and the fiscal outlook for this year appears likely to be better than implied by the most optimistic scenarios of previous projections. Eighteen months ago, the objective was set in the government’s Fiscal policy statement to halt the increase in debt to GDP ratio no later than by year-en
Intervest Offices & Warehouses NV: announces the departure in mutual agreement of Gunther Gielen as CEO29.3.2023 20:05:18 CEST | Press release
The mandate of Gunther Gielen as CEO with Intervest Offices & Warehouses NV ends in mutual agreement and with immediate effect. Attachment PR_GG_ENG
Nokia Corporation: Repurchase of own shares on 29.03.202329.3.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 29 March 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.03.2023 Espoo, Finland – On 29 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL231,0134.39CEUX38,2144.38AQEU9,7344.37TQEX21,5394.39Total300,5004.39 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 a
Zealand Pharma's Annual General Meeting 202329.3.2023 20:00:00 CEST | Press release
Company announcement – No. 9 / 2023 Zealand Pharma's Annual General Meeting 2023 Copenhagen, March 29, 2023 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting of 2023 as a partly electronic general meeting. At the meeting, all proposals presented to the General Meeting were adopted. The General Meeting acknowledged the management's report on Zealand's activities in the past financial year and Zealand's audited Annual Report for 2022 was approved. The meeting also approved that the financial result for 2022, which was a loss of TDKK 1,202,135, was carried forward to the next financial year. All the incumbent board members were re-elected as recommended by the Nomination Committee. Hence, Zealand's Board of Directors consists of the following members: Alf Gunnar Martin Nicklasson Kirsten Aarup Drejer Alain MunozJeffrey Berkowitz Michael John Owen Leonard KruimerBernadette Mary Connaughton After the Annual General Meeting, the Boa
Restricted Share Unit Programs29.3.2023 19:58:36 CEST | Press release
Company announcement for ROCKWOOL A/S Release no. 06 - 2023 to Nasdaq Copenhagen 29 March 2023 Restricted Share Unit Programs The ROCKWOOL A/S Board of Directors has today, in accordance with the remuneration policy adopted at the Annual General Meeting 2020, decided to allocate Restricted Share Units, including phantom units, (“RSUs”) to a group of up to 85 key employees in leading positions, including Group Management (the “Participants”). The scheme is designed to align the interest of the Participants to those of our shareholders, and to give the Participants an incentive to make a long-term commitment as well as to promote value creation within the group. The Board of Directors has granted the Participants a total of 12,900 RSUs and, subject to vesting, each RSU entitles the holder to receive one ROCKWOOL B-share or, in case of phantom units, a cash based settlement to the corresponding share value at the time of transfer. The fair value of each RSU is DKK 1,618.63 being the 15 da